Regeneron's earnings boosted by more than doubling of U.S. sales of blockbuster eye drug Eylea
Sales of Eylea, which the company co-developed with Bayer (DE:BAYA), rose 2% to $1.495 billion. Sales of the higher-dose, longer-lasting formulation Eylea HD rose 148% to $305 million in the U.S., ...
Regeneron projects EYLEA HD growth with new approvals and prefilled syringe launch in 2025
EYLEA HD is anticipated to gain traction with the launch of a prefilled syringe in mid-2025 and label expansions for macular edema and extended dosing intervals. Management believes these developments ...
RFK Jr. has questioned vaccines in the US. What is recommended in Michigan?
The U.S. Senate Finance Committee could vote as soon as Tuesday on Robert F. Kennedy Jr.’s controversial nomination to be ...
Cardio Diagnostics Expands the Reach of its AI-Driven Precision Cardiovascular Medicine Tests by Partnering with Seven New Provider Organizations
A practice in Texas, that employs concierge-level of care personalized for the patient and offers a holistic medicine approach. This practice emphasizes prevention, reduction of hospital admissions ...
ayradvertiser11h
Girvan Community Hospital offering COPD testing pilot
Spirometry testing is used in the diagnosis of various lung conditions such as chronic obstructive pulmonary disease (COPD). Tuesday, January 28 saw the first patients attend the ...
Regeneron's SWOT analysis: biotech giant's stock faces eylea challenges, pipeline promise
Pharmaceuticals, a leading biotechnology company with a market capitalization of $71.75 billion, has been navigating a complex landscape of opportunities and challenges in recent months. According to ...